Literature DB >> 1693147

Cell-free synthesis of glycosyl-phosphatidylinositol precursors for the glycolipid membrane anchor of Trypanosoma brucei variant surface glycoproteins. Structural characterization of putative biosynthetic intermediates.

A K Menon1, R T Schwarz, S Mayor, G A Cross.   

Abstract

Trypanosome variant surface glycoproteins exemplify a class of eukaryotic cell surface glycoproteins that rely on a carboxyl-terminal covalently-attached inositol-containing glycophospholipid for membrane attachment. The glycolipid anchor is acquired soon after translation of the polypeptide, apparently by replacement of a short carboxyl-terminal peptide sequence with a prefabricated glycolipid. A candidate glycolipid precursor (referred to as P2), and a related glycolipid (P3) have been identified recently in polar lipid extracts from trypanosomes. In this paper we describe the synthesis of P2 and P3 by trypanosome membranes. Analyses of organic solvent extracts from membranes incubated with radioactive sugar nucleotides (GDP-[3H]mannose or UDP-[3H]GlcNAc) showed a spectrum of labelled lipids, ranging from partially glycosylated species to the final products, P2 and P3. Structural analyses of these putative biosynthetic intermediates suggest that glycolipid assembly occurs via the sequential glycosylation of phosphatidylinositol.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1693147

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  38 in total

1.  Glycosylphosphatidylinositol biosynthesis validated as a drug target for African sleeping sickness.

Authors:  M A Ferguson
Journal:  Proc Natl Acad Sci U S A       Date:  2000-09-26       Impact factor: 11.205

2.  Specificity of GlcNAc-PI de-N-acetylase of GPI biosynthesis and synthesis of parasite-specific suicide substrate inhibitors.

Authors:  T K Smith; A Crossman; C N Borissow; M J Paterson; A Dix; J S Brimacombe; M A Ferguson
Journal:  EMBO J       Date:  2001-07-02       Impact factor: 11.598

Review 3.  Lipid metabolism in Trypanosoma brucei.

Authors:  Terry K Smith; Peter Bütikofer
Journal:  Mol Biochem Parasitol       Date:  2010-04-09       Impact factor: 1.759

4.  Conversion of human interferon-beta from a secreted to a phosphatidylinositol anchored protein by fusion of a 17 amino acid sequence to its carboxyl terminus.

Authors:  G E Santillán; M J Sandoval; Y Chernajovsky; P L Orchansky
Journal:  Mol Cell Biochem       Date:  1992-03-25       Impact factor: 3.396

5.  Early steps in glycosylphosphatidylinositol biosynthesis in Leishmania major.

Authors:  T K Smith; F C Milne; D K Sharma; A Crossman; J S Brimacombe; M A Ferguson
Journal:  Biochem J       Date:  1997-09-01       Impact factor: 3.857

6.  Biosynthesis of glycosylphosphatidylinositols of Plasmodium falciparum in a cell-free incubation system: inositol acylation is needed for mannosylation of glycosylphosphatidylinositols.

Authors:  P Gerold; N Jung; N Azzouz; N Freiberg; S Kobe; R T Schwarz
Journal:  Biochem J       Date:  1999-12-15       Impact factor: 3.857

7.  The glycosylphosphatidylinositol (GPI) biosynthetic pathway of bloodstream-form Trypanosoma brucei is dependent on the de novo synthesis of inositol.

Authors:  Kirstee L Martin; Terry K Smith
Journal:  Mol Microbiol       Date:  2006-07       Impact factor: 3.501

8.  Biosynthesis of the glycolipid anchor of lipophosphoglycan and the structurally related glycoinositolphospholipids from Leishmania major.

Authors:  L Proudfoot; P Schneider; M A Ferguson; M J McConville
Journal:  Biochem J       Date:  1995-05-15       Impact factor: 3.857

9.  The fatty acids in unremodelled trypanosome glycosyl-phosphatidylinositols.

Authors:  T L Doering; M S Pessin; G W Hart; D M Raben; P T Englund
Journal:  Biochem J       Date:  1994-05-01       Impact factor: 3.857

10.  Parasite and mammalian GPI biosynthetic pathways can be distinguished using synthetic substrate analogues.

Authors:  T K Smith; D K Sharma; A Crossman; A Dix; J S Brimacombe; M A Ferguson
Journal:  EMBO J       Date:  1997-11-17       Impact factor: 11.598

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.